UC Davis IP Spins Out into Venture & Secures $5 Million

Chronic Pain

UC Davis, CA-based venture targeting chronic pain receives a $5 million investment from Open Philanthropy.  The goal is to move research from UC Davis lab to human clinical trials reports Maggie Avants from Patch.

Davis-based EicOsis LLC seeks to block chronic pain in humans and companion animals. It has received $5 million from Open Philanthropy to move original research from the laboratory of Bruce Hammock of UC Davis into clinical trials. Known as EC5026, the drug candidate is a novel pathway to block underlying pain types. The new venture has been set up to commercialize the drug.  Clinical trials are expected this summer. EicOsis LLC describes the compound as a “novel, non-opioid and oral therapy for neuropathic and inflammatory pain.” Ms. Avants notes it is an inhibitor to soluble epoxide hydrolase (she) enxyme—apparently a regulatory enzyme involved in fatty acids metabolism.   Ms. Avants notes that UC Davis licensed certain patents that support the technology transfer to EicOsis.


This site uses Akismet to reduce spam. Learn how your comment data is processed.